IL125895A - Use of an image-enhancing moiety in the preparation of a bioactivated nmr or optical imaging contrast agent from a prodrug - Google Patents

Use of an image-enhancing moiety in the preparation of a bioactivated nmr or optical imaging contrast agent from a prodrug

Info

Publication number
IL125895A
IL125895A IL12589597A IL12589597A IL125895A IL 125895 A IL125895 A IL 125895A IL 12589597 A IL12589597 A IL 12589597A IL 12589597 A IL12589597 A IL 12589597A IL 125895 A IL125895 A IL 125895A
Authority
IL
Israel
Prior art keywords
prodrug
contrast agent
bioactivated
protein
iem
Prior art date
Application number
IL12589597A
Other languages
English (en)
Other versions
IL125895A0 (en
Inventor
Stuphane Dumas
Stephen O Dunham
Randall B Lauffer
Thomas J Mcmurry
David J Parmelee
Daniel M Scott
Original Assignee
Epix Medical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epix Medical Inc filed Critical Epix Medical Inc
Publication of IL125895A0 publication Critical patent/IL125895A0/xx
Publication of IL125895A publication Critical patent/IL125895A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/06Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/06Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10Organic compounds
    • A61K49/14Peptides, e.g. proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/0002General or multifunctional contrast agents, e.g. chelated agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/001Preparation for luminescence or biological staining
    • A61K49/0013Luminescence
    • A61K49/0017Fluorescence in vivo
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/001Preparation for luminescence or biological staining
    • A61K49/0013Luminescence
    • A61K49/0017Fluorescence in vivo
    • A61K49/0019Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/06Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/085Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/06Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/06Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10Organic compounds
    • A61K49/101Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/103Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being acyclic, e.g. DTPA
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/06Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10Organic compounds
    • A61K49/101Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/106Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL12589597A 1996-04-01 1997-03-25 Use of an image-enhancing moiety in the preparation of a bioactivated nmr or optical imaging contrast agent from a prodrug IL125895A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1444896P 1996-04-01 1996-04-01
PCT/US1997/004804 WO1997036619A2 (en) 1996-04-01 1997-03-25 Bioactivated diagnostic imaging contrast agents

Publications (2)

Publication Number Publication Date
IL125895A0 IL125895A0 (en) 1999-04-11
IL125895A true IL125895A (en) 2001-09-13

Family

ID=21765541

Family Applications (1)

Application Number Title Priority Date Filing Date
IL12589597A IL125895A (en) 1996-04-01 1997-03-25 Use of an image-enhancing moiety in the preparation of a bioactivated nmr or optical imaging contrast agent from a prodrug

Country Status (19)

Country Link
US (3) US6709646B2 (ja)
EP (1) EP0907379B1 (ja)
JP (2) JP2000507577A (ja)
KR (1) KR20060025233A (ja)
CN (1) CN1108824C (ja)
AT (1) ATE268187T1 (ja)
AU (1) AU726914B2 (ja)
BR (1) BR9708470A (ja)
CA (1) CA2247620A1 (ja)
DE (1) DE69729380T2 (ja)
DK (1) DK0907379T3 (ja)
ES (1) ES2217408T3 (ja)
HK (1) HK1016877A1 (ja)
IL (1) IL125895A (ja)
IS (1) IS2059B (ja)
NO (1) NO319674B1 (ja)
NZ (1) NZ331629A (ja)
PT (1) PT907379E (ja)
WO (1) WO1997036619A2 (ja)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6713045B1 (en) 1995-06-02 2004-03-30 Research Corporation Technologies, Inc. Targeted magnetic resonance imaging agents for the detection of physiological processes
US6770261B2 (en) * 1995-06-02 2004-08-03 Research Corporation Technologies Magnetic resonance imaging agents for the detection of physiological agents
US5900228A (en) 1996-07-31 1999-05-04 California Institute Of Technology Bifunctional detection agents having a polymer covalently linked to an MRI agent and an optical dye
US6675035B1 (en) * 1997-06-20 2004-01-06 Imaging Diagnostic Systems, Inc. Phantom for optical and magnetic resonance imaging quality control
IL134985A0 (en) * 1997-10-02 2001-05-20 Epix Medical Inc A method for contrast enhanced diagnostic imaging
US6713046B1 (en) 1997-10-27 2004-03-30 Research Corporation Technologies Magnetic resonance imaging agents for the delivery of therapeutic agents
JP2001521011A (ja) * 1997-10-27 2001-11-06 カリフォルニア・インスティテュート・オブ・テクノロジー 治療成分送達のための磁気共鳴イメージング剤
AU752812B2 (en) * 1997-11-17 2002-10-03 Research Corporation Technologies, Inc. Magnetic resonance imaging agents for the detection of physiological agents
IT1297035B1 (it) * 1997-12-30 1999-08-03 Bracco Spa Derivati dell'acido 1,4,7,10-tetraazaciclododecan-1,4-diacetico
IT1297034B1 (it) * 1997-12-30 1999-08-03 Bracco Spa Acido 1,4,7,10-tetraazaciclododecan-1,4-diacetico
US6167297A (en) 1999-05-05 2000-12-26 Benaron; David A. Detecting, localizing, and targeting internal sites in vivo using optical contrast agents
US6230586B1 (en) * 1999-05-21 2001-05-15 Chung-Hsi Chang Electric drive device for a bicycle
HUP0202635A3 (en) 1999-07-29 2006-03-28 Epix Medical Inc Cambridge Targeting multimeric imaging agents through multilocus binding
JP2003520255A (ja) * 2000-01-22 2003-07-02 エピックス メディカル, インコーポレイテッド 酵素的な切断によって生理活性化される造影剤プロドラッグを使用した磁気共鳴画像法
US6656448B1 (en) 2000-02-15 2003-12-02 Bristol-Myers Squibb Pharma Company Matrix metalloproteinase inhibitors
US20040146463A1 (en) * 2000-05-04 2004-07-29 Meade Thomas J. Functional MRI agents for cancer imaging
US6673333B1 (en) * 2000-05-04 2004-01-06 Research Corporation Technologies, Inc. Functional MRI agents for cancer imaging
EP1278553A2 (en) * 2000-05-04 2003-01-29 Research Corporation Technologies, Inc Magnetic resonance imaging agents for the delivery of therapeutic agents
EP1283728A2 (en) * 2000-05-23 2003-02-19 Amersham Health AS Contrast agents
US6748259B1 (en) 2000-06-15 2004-06-08 Spectros Corporation Optical imaging of induced signals in vivo under ambient light conditions
AU2001276956A1 (en) 2000-07-17 2002-01-30 California Institute Of Technology Macrocyclic mri contrast agents
WO2002028441A2 (en) 2000-10-04 2002-04-11 California Institute Of Technology Magnetic resonance imaging agents for in vivo labeling and detection of amyloid deposits
US20030004236A1 (en) * 2001-04-20 2003-01-02 Meade Thomas J. Magnetic resonance imaging agents for detection and delivery of therapeutic agents and detection of physiological substances
WO2002087632A1 (en) * 2001-05-02 2002-11-07 Metaprobe, Inc. High throughput screening methods using magnetic resonance imaging agents
TWI221406B (en) 2001-07-30 2004-10-01 Epix Medical Inc Systems and methods for targeted magnetic resonance imaging of the vascular system
ES2506142T3 (es) 2002-03-01 2014-10-13 Dyax Corp. Péptidos de unión a KDR y a VEGF/KDR y su uso en diagnóstico
US7261876B2 (en) 2002-03-01 2007-08-28 Bracco International Bv Multivalent constructs for therapeutic and diagnostic applications
EP1587944A4 (en) 2002-03-01 2007-03-21 Dyax Corp KDR AND VEGF / KDR BINDING PEPTIDES AND THEIR USE FOR DIAGNOSTIC AND THERAPEUTIC PURPOSES
US8623822B2 (en) 2002-03-01 2014-01-07 Bracco Suisse Sa KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
US7794693B2 (en) 2002-03-01 2010-09-14 Bracco International B.V. Targeting vector-phospholipid conjugates
US20030198597A1 (en) * 2002-04-22 2003-10-23 Meade Thomas J. Novel macrocyclic activatible magnetic resonance imaging contrast agents
AU2003251436A1 (en) * 2002-07-22 2004-02-09 Bracco Imaging S.P.A. Procedures of cellular labelling with paramagnetic complexes for mri applications
US20050163821A1 (en) * 2002-08-02 2005-07-28 Hsing-Wen Sung Drug-eluting Biodegradable Stent and Delivery Means
US7226577B2 (en) 2003-01-13 2007-06-05 Bracco Imaging, S. P. A. Gastrin releasing peptide compounds
DK2284180T3 (en) 2003-03-03 2015-12-21 Dyax Corp Uses of peptides that specifically bind to the HGF receptor (cMET)
EP2338525A3 (en) * 2003-07-09 2011-08-03 California Pacific Medical Center Remote detection of substance delivery to cells
US20050106100A1 (en) * 2003-09-03 2005-05-19 Harris Thomas D. Compounds containing matrix metalloproteinase substrates and methods of their use
US20050124008A1 (en) * 2003-12-05 2005-06-09 Kauvar Lawrence M. Homogeneous competition assays
NO20035683D0 (no) * 2003-12-18 2003-12-18 Amersham Health As Optisk avbildning av prostatakreft
FR2868320B1 (fr) * 2004-03-31 2007-11-02 Centre Nat Rech Scient Cnrse Agent de contraste pour l'imagerie par resonance magnetique
JP4975013B2 (ja) 2005-03-11 2012-07-11 ウエイク・フオレスト・ユニバーシテイ・ヘルス・サイエンシズ 組織が工作された心臓弁の製造
US8728463B2 (en) * 2005-03-11 2014-05-20 Wake Forest University Health Science Production of tissue engineered digits and limbs
US20060204539A1 (en) 2005-03-11 2006-09-14 Anthony Atala Electrospun cell matrices
US20060204445A1 (en) * 2005-03-11 2006-09-14 Anthony Atala Cell scaffold matrices with image contrast agents
US7531503B2 (en) * 2005-03-11 2009-05-12 Wake Forest University Health Sciences Cell scaffold matrices with incorporated therapeutic agents
CA2602029C (en) * 2005-03-11 2014-07-15 Wake Forest University Health Sciences Tissue engineered blood vessels
AU2006266074A1 (en) * 2005-06-30 2007-01-11 Bristol-Myers Squibb Pharma Company Hydrazide conjugates as imaging agents
EP1745739A3 (en) 2005-07-14 2009-04-22 Bundesrepublik Deutschland, vertr. d.d. Bundes- ministerium f. Wirtschaft- und Technologie, dieses vertr. d.d. Präs. d. Phys.-Techn. Bundesanstalt Optical imaging of rheumatoid arthritis
JP5377965B2 (ja) 2005-09-09 2013-12-25 ジョージア ステート ユニバーシティ リサーチ ファウンデーション、インコーポレイテッド 標的化された造影剤および造影剤を標的化するための方法
WO2007084264A2 (en) * 2005-12-29 2007-07-26 Epix Pharmaceuticals, Inc. Methods for myocardial imaging
US9193763B2 (en) 2007-08-17 2015-11-24 Purdue Research Foundation PSMA binding ligand-linker conjugates and methods for using
WO2009054327A1 (ja) * 2007-10-22 2009-04-30 Osaka Foundation For Trade And Industry Mri用プローブ
US20120045393A1 (en) 2009-03-17 2012-02-23 Linder Karen E Lhrh-ii peptide analogs
AR075900A1 (es) 2009-03-19 2011-05-04 Wyeth Llc Metodos para la preparacion de acidos (2-(8,9-dioxo-2,6-diazabiciclico (5.2.0) non-1(7)-en-2-il)etil) fosfonico y sus precursores.
WO2010121133A2 (en) 2009-04-17 2010-10-21 The General Hospital Corporation Multimodal imaging of fibrin
JP2011026294A (ja) 2009-06-26 2011-02-10 Canon Inc 化合物
WO2011035140A1 (en) 2009-09-18 2011-03-24 Paka Pulmonary Pharmaceuticals, Inc. Methods and compositions for delivery of contrast moieties to the lungs
US9951324B2 (en) 2010-02-25 2018-04-24 Purdue Research Foundation PSMA binding ligand-linker conjugates and methods for using
CN102188722A (zh) * 2010-03-18 2011-09-21 中国科学院福建物质结构研究所 一种含二价铁的磁共振成像造影剂
US8192429B2 (en) 2010-06-29 2012-06-05 Theravant, Inc. Abnormality eradication through resonance
EP2822602B1 (en) 2012-03-08 2020-06-03 Thommen Medical Ag Chewing gum for the diagnosis of inflammatory tissues in dental applications
WO2013131994A2 (en) * 2012-03-08 2013-09-12 Thommen Medical Ag Coating for the diagnosis of inflammatory tissues in dental applications
US9636413B2 (en) 2012-11-15 2017-05-02 Endocyte, Inc. Conjugates for treating diseases caused by PSMA expressing cells
US10092679B2 (en) 2013-10-18 2018-10-09 Wake Forest University Health Sciences Laminous vascular constructs combining cell sheet engineering and electrospinning technologies
MX2016005013A (es) 2013-10-18 2017-02-28 Deutsches Krebsforsch Inhibidores marcados de antigeno prostatico especifico de membrana (psma), su uso como agentes formadores de imagenes y agentes farmaceuticos para el tratamiento de cancer de prostata.
WO2015171543A1 (en) 2014-05-05 2015-11-12 California Institute Of Technology Mutant akt-specific capture agents, compositions, and methods of using and making
WO2015196208A2 (en) 2014-06-20 2015-12-23 The General Hospital Corporation Collagen targeted imaging probes
US10188759B2 (en) 2015-01-07 2019-01-29 Endocyte, Inc. Conjugates for imaging
US9913875B2 (en) 2015-03-16 2018-03-13 California Institute Of Technology Botulinum neurotoxin-specific capture agents, compositions, and methods of using and making
WO2017011769A2 (en) 2015-07-15 2017-01-19 California Institute Of Technology Il-17f-specific capture agents, compositions, and methods of using and making
EP3440101B1 (en) 2016-04-04 2021-10-06 Indi Molecular, Inc. Cd8-specific capture agents, compositions, and methods of using and making
WO2018064597A1 (en) 2016-09-29 2018-04-05 Indi Molecular, Inc. Compositions for detection, inhibition and imaging of indoleamine 2,3-dioxygenase 1 (ido1) and methods of making and using same
WO2018085375A1 (en) 2016-11-01 2018-05-11 Ohio State Innovation Foundation Methods for the iodination of biomolecules
JP2020517584A (ja) * 2017-04-27 2020-06-18 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 修飾mri造影剤およびその使用
EP3638687A1 (en) 2017-06-15 2020-04-22 Indi Molecular, Inc. Il-17f and il-17a-specific capture agents, compositions, and methods of using and making
WO2019075213A1 (en) * 2017-10-11 2019-04-18 Northwestern University HEPARIN CONJUGATED TO PEPTIDES BINDING TO COLLAGEN FOR TARGETING BIOLOGICAL AND SYNTHETIC FABRICS
CN108314695B (zh) * 2018-01-04 2020-06-16 南京邮电大学 一种异种双核金属配合物的制备及应用
US11919972B2 (en) 2018-11-02 2024-03-05 Regeneron Pharmaceuticals, Inc. Peptide libraries with non-canonical amino acids
US11638764B2 (en) 2018-11-08 2023-05-02 Indi Molecular, Inc. Theranostic capture agents, compositions, and methods of using and making
US20200291391A1 (en) 2019-03-12 2020-09-17 Indi Molecular, Inc. Cross-linked epitopes and methods of use thereof
US20220218834A1 (en) 2019-05-20 2022-07-14 Ohio State Innovation Foundation Apohemoglobin-haptoglobin complexes and methods of using thereof
WO2020236969A1 (en) 2019-05-20 2020-11-26 Indi Molecular, Inc. Compositions and methods relating to detection, inhibition, and imaging of indoleamine 2,3-dioxygenase 1 (ido1)
US11414460B2 (en) 2019-07-19 2022-08-16 Institute For Systems Biology KRAS-specific capture agents, compositions, and methods of making and using
CN112891566A (zh) * 2019-12-04 2021-06-04 中国科学院宁波工业技术研究院慈溪生物医学工程研究所 一种纳米材料及其制备方法和包含其的造影剂
AU2021265205A1 (en) 2020-04-30 2023-01-05 Academisch Ziekenhuis Groningen Anti-CD103 antibodies
WO2022098745A1 (en) 2020-11-03 2022-05-12 Indi Molecular, Inc. Compositions, delivery systems, and methods useful in tumor therapy
WO2022098743A1 (en) 2020-11-03 2022-05-12 Indi Molecular, Inc. Compositions, imaging, and therapeutic methods targeting folate receptor 1 (folr1)

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4899755A (en) 1985-05-08 1990-02-13 The General Hospital Corporation Hepatobiliary NMR contrast agents
US4880008A (en) 1985-05-08 1989-11-14 The General Hospital Corporation Vivo enhancement of NMR relaxivity
WO1988002635A1 (en) * 1986-10-17 1988-04-21 Cytogen Corporation Method for preparation of protein-chelator-metal ion compositions suitable for injection
US4904768A (en) 1987-08-04 1990-02-27 Bristol-Myers Company Epipodophyllotoxin glucoside 4'-phosphate derivatives
US5171563A (en) 1988-09-30 1992-12-15 Neorx Corporation Cleavable linkers for the reduction of non-target organ retention of immunoconjugates
US5094848A (en) * 1989-06-30 1992-03-10 Neorx Corporation Cleavable diphosphate and amidated diphosphate linkers
WO1991003200A1 (en) * 1989-08-28 1991-03-21 The General Hospital Corporation Hydroxy-aryl metal chelates for diagnostic nmr imaging
USH1312H (en) * 1992-05-28 1994-05-03 Cytogen Corporation Method for the preparation of gyk-dtpa
EP0664713B1 (en) * 1992-10-14 2000-01-19 Nycomed Imaging As Therapeutic and diagnostic imaging compositions and methods
DE4341724A1 (de) * 1993-12-03 1995-06-08 Schering Ag Halogenaryl-substituierte Metallkomplexe enthaltende pharmazeutische Mittel, deren Verwendung in der Diagnostik, sowie Verfahren zur Herstellung der Komplexe und Mittel
JPH09505819A (ja) * 1993-12-03 1997-06-10 ブラッコ エッセ.ピ.ア. 核磁気共鳴診断用常磁性キレート
TW319763B (ja) * 1995-02-01 1997-11-11 Epix Medical Inc
DE19507822B4 (de) * 1995-02-21 2006-07-20 Schering Ag Substituierte DTPA-Monoamide der zentralen Carbonsäure und deren Metallkomplexe, diese Komplexe enthaltende pharmazeutische Mittel, deren Verwendung in der Diagnostik und Therapie sowie Verfahren zur Herstellung der Komplexe und Mittel
US5846743A (en) 1995-02-22 1998-12-08 Brigham And Women's Hospital, Inc. Polyphoshoinositide binding peptides for intracellular drug delivery
US5707605A (en) * 1995-06-02 1998-01-13 Research Corporation Technologies Magnetic resonance imaging agents for the detection of physiological agents

Also Published As

Publication number Publication date
IL125895A0 (en) 1999-04-11
IS4833A (is) 1998-08-26
JP2004210796A (ja) 2004-07-29
KR20060025233A (ko) 2006-03-20
WO1997036619A2 (en) 1997-10-09
JP2000507577A (ja) 2000-06-20
ES2217408T3 (es) 2004-11-01
ATE268187T1 (de) 2004-06-15
WO1997036619A3 (en) 1998-01-29
EP0907379B1 (en) 2004-06-02
NO984543D0 (no) 1998-09-29
DK0907379T3 (da) 2004-08-16
DE69729380D1 (de) 2004-07-08
BR9708470A (pt) 1999-04-13
EP0907379A2 (en) 1999-04-14
US7147837B2 (en) 2006-12-12
NZ331629A (en) 2000-04-28
CN1108824C (zh) 2003-05-21
US20020034476A1 (en) 2002-03-21
PT907379E (pt) 2004-09-30
HK1016877A1 (en) 1999-11-12
NO984543L (no) 1998-11-26
IS2059B (is) 2005-10-14
US20040156785A1 (en) 2004-08-12
NO319674B1 (no) 2005-09-05
CN1215341A (zh) 1999-04-28
US20060275216A1 (en) 2006-12-07
AU2544897A (en) 1997-10-22
CA2247620A1 (en) 1997-10-09
AU726914B2 (en) 2000-11-23
US6709646B2 (en) 2004-03-23
DE69729380T2 (de) 2005-07-14

Similar Documents

Publication Publication Date Title
EP0907379B1 (en) Bioactivated diagnostic imaging contrast agents
AU742438C (en) Contrast-enhanced diagnostic imaging method for monitoring interventional therapies
EP0806968B1 (en) Diagnostic imaging contrast agents with extended blood retention
CN108368067B (zh) 二聚造影剂
Zhang et al. Gadolinium meets medicinal chemistry: MRI contrast agent development
ZA200108575B (en) Perfluoroalkylamide, the production thereof and the use thereof in diagnostics.
KR100593648B1 (ko) 생체활성화진단용영상콘트라스트제제
MXPA98008108A (en) Agents of image contrast for bioactive diagnosis
Reeßing et al. Alight-RESPONSIVE LIPOSOMAL
CA2539215A1 (en) Diagnostic imaging contrast agents with extended blood retention
AU3138702A (en) Contrast-enhanced diagnostic imaging method for monitoring interventional therapies
MXPA00002869A (en) Contrast-enhanced diagnostic imaging method for monitoring interventional therapies

Legal Events

Date Code Title Description
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees